secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-07-22T21:25:23+00:00
Accession:  0001213900-26-080474
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics completes enrollment of 750 patients in SYMON-II sepsis study ahead of schedule
--------------------------------------------------------------------------------

- Enrolled 750 patients ahead of plan in pivotal SYMON-II study evaluating Symphony IL-6 for early sepsis mortality risk assessment.
- Preliminary observations indicate an approximately 17% 28-day mortality rate, providing a robust clinical dataset.
- Study enrolled patients across leading U.S. healthcare institutions; results to support planned 510(k) submission to FDA.
- Company expects to complete data cleaning, statistical analysis, and clinical reporting over the coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026080474/0001213900-26-080474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026080474/ea0298955-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-080474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer